Yıl: 2023 Cilt: 53 Sayı: 6 Sayfa Aralığı: 1704 - 1712 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5739 İndeks Tarihi: 17-01-2024

Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis

Öz:
ackground/aim: B-cell depletion with rituximab (RTX) is widely used as a rescue therapy in patients with systemic sclerosis (SSc). The aim herein was to analyze the progress of disease-related outcomes after RTX therapy in severe SSc patients. Materials and methods: Included in this study were 27 SSc patients who were followed-up between 2012 and 2020 and received at least 1 cycle of RTX for active disease, despite receiving standard immunosuppressives (ISs). In addition to the European Scleroderma Study Group and European Scleroderma Trials and Research Group activity scores, Medsger’s severity, and the recently developed Scleroderma Clinical Trials Consortium Damage Index values were evaluated initially and at 1 year after the first infusion. The progress of individual organ damage was also assessed at the end of the follow-up period (at least 6 months after the last infusion) using the data extracted from the medical records. Results: Disease activity and severity-improved and disease-related overall damage worsened after the first year of RTX therapy (p < 0.001, p = 0.008, and p = 0.005). Some of the disease-related organ damage had improved at the end of the follow-up period, indicating its reversibility. Overall damage scores ≥11 after the first year of RTX therapy were found to be associated with mortality (p = 0.035). Conclusion: RTX contributed to reducing the activity and severity in SSc patients with severe disease, nonetheless the efficacy related to the damage was limited. High damage scores in the first year were found to be associated with mortality. Spontaneous progress of manifestations requiring a longer period to improve and irregular consecutive RTX courses might lead to difficulties in differentiation between activity and damage.
Anahtar Kelime: Systemic sclerosis rituximab disease related outcomes

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Allanore Y, Simms R, Distler O, Trojanowska M , Pope J et al. Systemic sclerosis. Nature Reviews Disease Primers 2015; 1: 15002. https://doi.org/10.1038/nrdp.2015.2
  • 2. Asano Y, Varga J. Rationally-based therapeutic disease modification in systemic sclerosis: novel strategies. Seminars in Cell and Developmental Biology 2020; 101: 146-160. https:// doi.org/10.1016/j.semcdb.2019.12.007
  • 3. Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018; 57 (12): 2106-2113. https://doi.org/10.1093/rheumatology/key213
  • 4. Narváez J, LLuch J, Molina-Molina M, Vicens-Zygmunt V, Luburich P et al. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis-associated interstitial lung disease unresponsive to conventional immunosuppression. Seminars and Arthritis Rheumatism 2020; 50 (5): 977-987. https://doi. org/10.1016/j.semarthrit.2020.08.004
  • 5. Erre GL, Sebastiani M, Fenu MA, Zinellu A, Floris A et al. Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis. Journal of Clinical Medicine 2020; 9 (8): 2560. https://doi.org/10.3390/ jcm9082560
  • 6. Smith V, Van Prae JT, Vandooren B, der Cruyssen BV, Naeyaert JM et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Annals of Rheumatic Diseases 2010; 69 (1): 193-197. https://doi. org/10.1136/ard.2008.095463
  • 7. Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Annals of Rheumatic Diseases 2015; 74 (6): 1188-1194. https://doi.org/10.1136/annrheumdis-2013-204522
  • 8. Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Seminars and Arthritis Rheumatism 2015; 44 (4): 428-436. https://doi. org/10.1016/j.semarthrit.2014.09.002
  • 9. Yoshizaki A. B lymphocytes in systemic sclerosis: abnormalities and therapeutic targets. The Journal of Dermatology 2016; 43 (1): 39-45. https://doi.org/10.1111/1346-8138.13184
  • 10. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clinical and Experimental Rheumatology 2003; 21 (3 Suppl 29): S39-S41. PMID: 12889221
  • 11. Valentini G, Iudici M, Walker UA, Jaeger VK, Jaeger VK et al. The European Scleroderma Trials and Research Group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Annals of Rheumatic Diseases 2017; 76 (1): 270-276. https:// doi.org/10.1136/annrheumdis-2016-209768
  • 12. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clinical and Experimental Rheumatology 2003; 21 (3 Suppl 29): S42-S46. PMID: 12889222
  • 13. Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M et al. Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. Annals of Rheumatic Diseases 2019; 78 (6): 807-816. https://doi. org/10.1136/annrheumdis-2018-214764
  • 14. Tang R, Yu J, Shi Y, Zou U, Zeng Z et al. Safety and efficacy of rituximab in systemic sclerosis: a systematic review and meta-analysis. International Immunopharmacology 2020; 83: 106389. https://doi.org/10.1016/j.intimp.2020.106389
  • 15. Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M et al. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of Rheumatic Diseases 2019; 78 (7): 979-987. https://doi.org/10.1136/annrheumdis-2018-214816
  • 16. Campochiaro C, De Luca G, Lazzaroni MG, Zanatta L, Bosello SL et al. Safety and efficacy of rituximab biosimilar (CT- P10) in systemic sclerosis: an Italian multicentre study. Rheumatology (Oxford) 2020; 59 (12): 3731-3736. https://doi. org/10.1093/rheumatology/keaa136
  • 17. Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica 2018; 73 (2): 119-125. https://doi.org/10.1080/17843286.2017.1372244
  • 18. Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A et al. Rituximab in early systemic sclerosis. RMD Open Rheumatic and Musculoskeletal Diseases 2017; 3 (2): e000384. https://doi. org/10.1136/rmdopen-2016-000384
APA yalcinkaya y, Artım Esen B, Amikishiyev S, Aliyeva N, Gül A, OÇAL M, Inanc M (2023). Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. , 1704 - 1712. 10.55730/1300-0144.5739
Chicago yalcinkaya yasemin,Artım Esen Bahar,Amikishiyev Shirkhan,Aliyeva Numune,Gül Ahmet,OÇAL MAHDUME LALE,Inanc Murat Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. (2023): 1704 - 1712. 10.55730/1300-0144.5739
MLA yalcinkaya yasemin,Artım Esen Bahar,Amikishiyev Shirkhan,Aliyeva Numune,Gül Ahmet,OÇAL MAHDUME LALE,Inanc Murat Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. , 2023, ss.1704 - 1712. 10.55730/1300-0144.5739
AMA yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. . 2023; 1704 - 1712. 10.55730/1300-0144.5739
Vancouver yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. . 2023; 1704 - 1712. 10.55730/1300-0144.5739
IEEE yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M "Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis." , ss.1704 - 1712, 2023. 10.55730/1300-0144.5739
ISNAD yalcinkaya, yasemin vd. "Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis". (2023), 1704-1712. https://doi.org/10.55730/1300-0144.5739
APA yalcinkaya y, Artım Esen B, Amikishiyev S, Aliyeva N, Gül A, OÇAL M, Inanc M (2023). Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turkish Journal of Medical Sciences, 53(6), 1704 - 1712. 10.55730/1300-0144.5739
Chicago yalcinkaya yasemin,Artım Esen Bahar,Amikishiyev Shirkhan,Aliyeva Numune,Gül Ahmet,OÇAL MAHDUME LALE,Inanc Murat Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turkish Journal of Medical Sciences 53, no.6 (2023): 1704 - 1712. 10.55730/1300-0144.5739
MLA yalcinkaya yasemin,Artım Esen Bahar,Amikishiyev Shirkhan,Aliyeva Numune,Gül Ahmet,OÇAL MAHDUME LALE,Inanc Murat Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turkish Journal of Medical Sciences, vol.53, no.6, 2023, ss.1704 - 1712. 10.55730/1300-0144.5739
AMA yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turkish Journal of Medical Sciences. 2023; 53(6): 1704 - 1712. 10.55730/1300-0144.5739
Vancouver yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis. Turkish Journal of Medical Sciences. 2023; 53(6): 1704 - 1712. 10.55730/1300-0144.5739
IEEE yalcinkaya y,Artım Esen B,Amikishiyev S,Aliyeva N,Gül A,OÇAL M,Inanc M "Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis." Turkish Journal of Medical Sciences, 53, ss.1704 - 1712, 2023. 10.55730/1300-0144.5739
ISNAD yalcinkaya, yasemin vd. "Efficacy of rituximab on disease activity, severity, and disease-related damage in patients with immunosuppressive-resistant systemic sclerosis". Turkish Journal of Medical Sciences 53/6 (2023), 1704-1712. https://doi.org/10.55730/1300-0144.5739